Pharma's Almanac TV
PA TV
Your Name
Your Email
Manage Account
Sign Out
Sign In
Register
Follow the Journey
Companies On The Road
Arcadis DPS Group
C2 Pharma
CAI
EcoLab
Environmental Systems Corporation
Federal Equipment Company
Globyz Biopharma Services
Grifols
Integrity
Nu-Tek BioSciences
PHARMALEX
Waters Corporation
Follow the Journey
Companies On The Road
ABS
aCGT Vector
Alconox Inc.
Andelyn Biosciences
Arranta Bio
Avid Bioservices
BDD
BIOVECTRA
DPS Group
Dynamk Capital
Environmental Systems Corporation
Federal Equipment Company
Genesis AEC
Globyz Biopharma Services
Grifols Partnership
IDT Biologika
Inceptor Bio
IPS-Integrated Project Services
Kineticos Life Sciences
MilliporeSigma
Montana BioScience Alliance
Olon
Rentschler Biopharma
SanaClis
Scorpion Biological Services
Secant Group
Tapemark
VITRONIC
Follow the Journey
Companies On The Road
AES Clean Technology
Altis Biosystems
Arranta Bio
Avara Pharmaceutical Services
Avid Bioservices
BioVectra
Centaur BPS
Dynamk Capital
ECRI
Evolve Biologics
Federal Equipment Company
Globyz
Inceptor Bio
IPS-Integrated Project Services
Olon
Pii
Polpharma Biologics
PPD
RoosterBio
SanaClis
Sanofi AIS
SGD Pharma
SPI Pharma
TriRx Pharmaceutical Services
Yourway
Dashboard
Topics
Products
ADC
API - Small Molecule
Biologics
Biopharmaceuticals
Biosimilars
Cell and Gene Therapy
DNA
Drug Product
Drug Substance
Equipment
Generics
Immunotherapy
Injectables
Monoclonal Antibody
Novel Therapeutics
Oral Solid Dosage
Orphan Drugs
Parenterals
Stem Cells
Vaccine
Services
Big Data
Bioprocessing
Clinical Trials
Continuous Manufacturing
Diagnostics
Drug Delivery
Drug Development
Drug Discovery
Facility
Formulation
Innovation
Oncology
Patient Adherence
Patient Centric
Preclinical
Process Development
Quality
Regulatory
Research
Serialization
Segment
Biomanufacturing
Biotechnology
CDMO
Consulting
CRO
Engineering
Equipment
Excipients
Healthcare
Intermediates
Logistics
Manufacturing
Packaging
Supply Chain
Business
Agreement
Appointment
Business
Capacity Expansion
Collaboration
Growth
Investment
Licensing
M&A
Market Expansion
Market Intelligence
Market Prediction
New Facility
Strategic Partnership
Magazine
Archive
Reports
Nice Insight Reports
2022 Sterile
2023 Cell & Gene Therapy
2023 mAb and Recombinant Protein
2024 API
2024 OSD
2024 ADC
2024 mRNA
2024 Mammalian Cell Culture
2024 Microbial Cell Culture
2024 Plasmids
2024 Gene Therapy
2024 Cell Therapy
2024 Sterile
Community
Company A to Z
Follow the Journey
Companies On The Road
Follow The Artist
Follow the Journey
Companies On The Road
More+
Staffing
Media Kit
Oncology (3)
401 Articles Available
3
17
Can't find what you're looking for? Try our
advanced search
.
Immunotherapy
Using a Natural Molecular Warning System to Fight Cancer and Infectious Diseases
PAP-Q2-20-CL-020
Cancer and Neurodegenerative Diseases
Leveraging the Cell Cytoskeleton for the Treatment of Cancer and Neurodegenerative Diseases
PAP-Q2-20-CL-024
Clinical Trials
FDA Announces First of Its Kind Pilot Program to Communicate Patient Reported Outcomes from Cancer Clinical Trials
PR-M06-20-NI-032
Oncology
Eli Lilly Drug Significantly Reduces the Risk of Breast Cancer Returning
PR-M06-20-NI-020
Oncology
Calquence Showed Long-Term Efficacy and Tolerability for Patients with Chronic Lymphocytic Leukemia in Two Trials
PR-M06-20-NI-019
Collaboration
AstraZeneca to Discover and Develop Novel Therapies Targeting RNA-Modifying Proteins in Oncology Collaboration with Accent Therapeutics
PR-M06-20-NI-005
Oncology
AstraZeneca Collaborates with ArcherDX to Use Personalized Cancer Assays to Detect Minimal Residual Disease in Lung Cancer Trials
PR-M05-20-NI-044
Cancer Treatment
HKBU-led Research Team Develops Novel Anti-viral Targeted Drug for Nasopharyngeal Cancer Treatment
PR-M05-20-NI-024
FDA Approval
Novartis Announces FDA Approval of MET Inhibitor Tabrecta™ for Metastatic Non-Small Cell Lung Cancer with METex14
PR-M05-20-NI-011
FDA Approval
Roche Receives FDA Approval for Cobas HPV Test to Identify Women at Risk for Cervical Cancer
PR-M04-20-NI-031
FDA Approval
Seattle Genetics Announces FDA Approval of TUKYSA for Breast Cancer
PR-M04-20-NI-028
PR-M03-20-NI-036
Vaccitech and Oxford University Announce Promising Phase 2a Data on Prostate Cancer Immunotherapy
PR-M03-20-NI-036
RNA Biomarkers
RNA Biomarkers for Early Lung Cancer Diagnosis
PAP-Q1-20-CL-014
In Conversation
In Conversation: NantKwest — Harnessing Natural Killer Cells to Treat Cancer
PAP-Q1-20-CL-016
Cancer Screening
Innovating to Increase Adherence for Colon Cancer Screening
PAP-Q1-20-CL-018
Digital Therapeutics
Voluntis and Bristol-Myers Squibb to Co-Develop Digital Therapeutics for Oncology
PR-M03-20-NI-011
Drug Development
Samsung Biologics and STCube Enter into Development and Manufacturing Agreement for Novel Target Anticancer Drug
PR-M03-20-NI-007
Priority Review
Novartis Lung Cancer Drug Granted Priority FDA Review
PR-M02-20-NI-010
Oncology
Dozens of Non-Oncology Drugs Can Kill Cancer Cells
PR-M01-20-NI-031
Cancer Breakthrough
Progress Report on Cancer Breakthroughs 2020 Project Presented by Dr. Soon-Shiong at J.P. Morgan Healthcare Conference
PR-M01-20-NI-026
Cancer Treatment
NantKwest and ImmunityBio Announce Complete Response in Metastatic Pancreatic Cancer Patient
PR-M01-20-NI-020
Drug Development
LYNPARZA® (olaparib) Approved by FDA as First-Line Maintenance Treatment of Germline BRCA-Mutated Metastatic Pancreatic Cancer
PR-M01-20-NI-003
Immunotherapy
NantKwest and ImmunityBio Present Results of Landmark Trial of First-in-Human Combination Immunotherapy in Triple Negative Breast Cancer
PR-M12-19-NI-022
Oncology
Simultaneous RNA and DNA Testing is More Effective than DNA Testing Alone
PAO-M12-19-NI-003
«
3
17
»
.svg)